ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Development and Analysis of a Nomogram for Predicting Pathological Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Cancer
Hongyi Yu
Yingjun Pu
Li Wang
Xianfu Li
Affiliated Hospital of North Sichuan Medical College, Nanchong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Background Neoadjuvant immunochemotherapy (NICT) has demonstrated potential to enhance tumor regression in patients with locally advanced gastric cancer (LAGC). However, the benefits for some patients are limited. Existing biological markers have only restricted ability to predict pathological response. New biomarkers and predictive models are essential for identifying patients optimally responsive to immunotherapy. Methods In our retrospective analysis, we included LAGC patients who underwent surgical treatment following NICT at our center between January 2021 and March 2025. Classification was done according to the pathological response rates observed in the excised tumor samples, categorizing patients into major pathological response (MPR) and non-MPR groups. Least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression models were used to pinpoint risk factors linked to MPR. A nomogram was subsequently constructed using the significant predictors. Results In total, 113 LAGC patients fitting the criteria were enrolled, with 46 in the MPR cohort and 67 in the non-MPR cohort, yielding an overall MPR incidence of 40.7%. Independent predictors of MPR following NICT were identified through multivariate logistic regression. These include pre-treatment tumor bed diameter < 3.75 cm (OR = 0.22), CEA < 1.765 ng/mL (OR = 0.26), CA19-9 < 18.390 U/mL (OR = 0.148), NLR < 2.422 (OR = 0.265), and SII < 597.483 (OR = 0.194). We constructed a nomogram model with an area under the curve of 0.848 (95% CI: 0.773–0.923) based on these five predictors. The calibration curve indicated a robust agreement between forecasted probabilities and real MPR occurrences (Hosmer–Lemeshow test: χ2 = 4.705, P = 0.789). Conclusion Tumor bed diameter, CEA, CA19-9, NLR, and SII were determined to be independent predictors of MPR in LAGC patients undergoing NICT. The constructed nomogram demonstrated good accuracy and clinical utility in predicting MPR after NICT, and may help guide the implementation of personalized treatment strategies.
Summary
Keywords
biomarkers, Immunotherapy, Locally advanced gastric cancer, major pathological response, Neoadjuvant Therapy, nomogram
Received
02 November 2025
Accepted
18 February 2026
Copyright
© 2026 Yu, Pu, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xianfu Li
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.